Epidemiological Study of Malignant Paediatric Liver Tumours in Denmark 1985-2020.
epidemiology
hepatoblastoma
liver tumours
paediatric
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jun 2023
26 Jun 2023
Historique:
received:
23
05
2023
revised:
20
06
2023
accepted:
22
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Malignant liver tumours in children are rare and national outcomes for this tumour entity are rarely published. This study mapped paediatric liver tumours in Denmark over 35 years and reported on the incidence, outcomes and long-term adverse events. We identified all liver tumours from the Danish Childhood Cancer Registry and reviewed the case records for patient and tumour characteristics, treatment and clinical outcome. We included 79 patients in the analyses. Overall crude incidence was ~2.29 per 1 million children (<15 yr) per year, with 61 hepatoblastomas (HB), 9 hepatocellular carcinomas and 9 other hepatic tumours. Overall 5-year survival was 84%, 78% and 44%, respectively. Nine patients had underlying liver disease or predisposition syndrome. Seventeen children underwent liver transplantation, with two late complications, biliary stenosis and liver fibrosis. For HB, age ≥ 8 years and diagnosis prior to 2000 were significant predictors of a poorer outcome. Adverse events included reduced renal function in 10%, reduced cardiac function in 6% and impaired hearing function in 60% (19% needed hearing aids). Behavioural conditions requiring additional support in school were registered in 10 children. In Denmark, incidences of malignant liver tumours during the last four decades have been increasing, as reported in the literature. HB survival has improved since the year 2000 and is comparable with international results. Reduced hearing is the major treatment-related side effect and affects approximately 60% of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant liver tumours in children are rare and national outcomes for this tumour entity are rarely published. This study mapped paediatric liver tumours in Denmark over 35 years and reported on the incidence, outcomes and long-term adverse events.
METHODS
METHODS
We identified all liver tumours from the Danish Childhood Cancer Registry and reviewed the case records for patient and tumour characteristics, treatment and clinical outcome.
RESULTS
RESULTS
We included 79 patients in the analyses. Overall crude incidence was ~2.29 per 1 million children (<15 yr) per year, with 61 hepatoblastomas (HB), 9 hepatocellular carcinomas and 9 other hepatic tumours. Overall 5-year survival was 84%, 78% and 44%, respectively. Nine patients had underlying liver disease or predisposition syndrome. Seventeen children underwent liver transplantation, with two late complications, biliary stenosis and liver fibrosis. For HB, age ≥ 8 years and diagnosis prior to 2000 were significant predictors of a poorer outcome. Adverse events included reduced renal function in 10%, reduced cardiac function in 6% and impaired hearing function in 60% (19% needed hearing aids). Behavioural conditions requiring additional support in school were registered in 10 children.
CONCLUSIONS
CONCLUSIONS
In Denmark, incidences of malignant liver tumours during the last four decades have been increasing, as reported in the literature. HB survival has improved since the year 2000 and is comparable with international results. Reduced hearing is the major treatment-related side effect and affects approximately 60% of patients.
Identifiants
pubmed: 37444465
pii: cancers15133355
doi: 10.3390/cancers15133355
pmc: PMC10341131
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Børnecancerfonden
ID : 2022-8175
Références
Clin Epidemiol. 2016 Oct 25;8:461-464
pubmed: 27822085
J Clin Oncol. 2020 Aug 1;38(22):2488-2498
pubmed: 32421442
J Clin Oncol. 2014 Feb 20;32(6):527-34
pubmed: 24419114
Clin Cancer Res. 2017 Jul 1;23(13):e107-e114
pubmed: 28674119
Lancet Oncol. 2017 Jan;18(1):122-131
pubmed: 27884679
Surg Oncol. 2007 Nov;16(3):195-203
pubmed: 17714939
Cancer Commun (Lond). 2019 Oct 24;39(1):62
pubmed: 31651371
Neurooncol Adv. 2020 Sep 15;2(1):vdaa122
pubmed: 33196041
J Pediatr Hematol Oncol. 2019 Apr;41(3):181-186
pubmed: 30557167
Front Biosci (Elite Ed). 2012 Jan 01;4(1):470-9
pubmed: 22201887
Clin Cancer Res. 2017 Jul 1;23(13):e115-e122
pubmed: 28674120
Hepatol Int. 2022 Feb;16(1):125-134
pubmed: 34506008
J Clin Oncol. 2005 Feb 20;23(6):1245-52
pubmed: 15718322
J Clin Oncol. 2016 Apr 1;34(10):1050-6
pubmed: 26811523
Pediatr Blood Cancer. 2004 Jan;42(1):74-83
pubmed: 14752798
Int J Cancer. 2012 Aug 15;131(4):E555-61
pubmed: 22095187
Cancer. 2006 Jul 15;107(2):417-22
pubmed: 16779793
Oncologist. 2008 Jul;13(7):812-20
pubmed: 18644850
Acta Paediatr. 2011 May;100(5):750-7
pubmed: 21158910
N Engl J Med. 2018 Jun 21;378(25):2376-2385
pubmed: 29924955
Int J Mol Sci. 2023 Feb 21;24(5):
pubmed: 36901689
Hepatology. 2006 Aug;44(2):478-86
pubmed: 16871584
Cancer. 2008 Jan 15;112(2):416-32
pubmed: 18074355
Lancet Child Adolesc Health. 2019 Aug;3(8):578-584
pubmed: 31160205
Lancet Oncol. 2013 Aug;14(9):834-42
pubmed: 23831416
Pediatr Blood Cancer. 2022 Jan;69(1):e29425
pubmed: 34736292
Pediatr Blood Cancer. 2011 Dec 15;57(7):1270-5
pubmed: 21910210
Acta Paediatr. 2020 Feb;109(2):404-414
pubmed: 31350767
Ugeskr Laeger. 2008 Apr 14;170(16):1366-9
pubmed: 18433603
Lancet Oncol. 2019 Jan;20(1):e29-e41
pubmed: 30614474
Lancet Child Adolesc Health. 2020 Feb;4(2):141-150
pubmed: 31866182
Cancers (Basel). 2019 Nov 11;11(11):
pubmed: 31718024
Eur J Cancer. 2016 Jan;52:92-101
pubmed: 26655560
JAMA Surg. 2015 Dec;150(12):1150-8
pubmed: 26308249